Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00249041 | Enbrel Liquid Immunogenicity Protocol | PHASE3 | COMPLETED | 447 | — | — | Oct 1, 2005 | Mar 1, 2007 | Jul 30, 2010 | - | — |
| Arm | Type | Description |
|---|---|---|
| Etanercept liquid | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 50 mg Etanercept | DRUG | 50 mg Etanercept liquid injected SC once weekly using prefilled syringes |
| Enbrel liquid | DRUG | 50 mg Etanercept liquid injected SC once weekly using prefilled syringes |
Inclusion Criteria: * 18 years of age or older * Must be able to self-inject or have someone who can do so for them * Should have Rheumatoid Arthritis per ARA criteria and screening lab results per predefined value Exclusion Criteria: * Any prior biologic therapy for inflammatory disease * Any pr...